Compare Repligen Corporation Common Stock (RGEN) vs Vanguard Growth Index Fund ETF (VUG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Repligen Corporation Common Stock vs Vanguard Growth Index Fund ETF — how do they compare? Repligen Corporation Common Stock trades at $178.86 (market cap $11.14B), while Vanguard Growth Index Fund ETF trades at $89.49 (market cap $384.60B). The key difference: Vanguard Growth Index Fund ETF is far larger — about 34.5× Repligen Corporation Common Stock's market cap, and Vanguard Growth Index Fund ETF is more actively traded (4,518,036 versus 1,259,263). Which is the better fit depends on your goals — on Pluang, investors hold Repligen Corporation Common Stock for 0 Days and Vanguard Growth Index Fund ETF for 47 Days on average.
| RGEN | VUG | |
|---|---|---|
Market Cap | $11.14B | $384.60B |
Volume | 1,259,263 | 4,518,036 |
Sector | Health | Sector/Thematic |
52-Week High | $194.57 | $92.64 |
52-Week Low | $102.87 | $70.00 |
Typical Hold Time | 0 Days | 47 Days |
Enterprise Value | $11.02B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
VUG trades at $91.75, up 0.12% with a bullish technical outlook supported by moving averages. The ETF maintains strong historical performance with 12% average annual returns since 2004, concentrated in mega-cap technology stocks like Nvidia, Apple, and Microsoft. Recent dividend activity shows a $0.09 distribution scheduled for September 2026.
Long-term growth prospects remain favorable given VUG's track record and low expense ratio, though concentration risk in technology holdings and recent underperformance versus value funds present headwinds. The ETF suits investors with multi-decade horizons seeking large-cap growth exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →About Vanguard Growth Index Fund ETF
VUG is an index-based ETF that tracks the CRSP US Large Cap Growth Index, providing concentrated exposure to the largest and fastest-growing companies in the United States. It focuses on stocks with high growth potential across tech, communication, and consumer sectors, serving as a low-cost, high-conviction core holding for long-term capital appreciation.
Read more on VUG →
